📰 Track Designations News
Track Designations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Track Designations. Real-time updates on events, politics, business and more.
March 28, 2024
Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for...
March 28, 2024
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...
March 26, 2024
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurologyStrong balance sheet, bolstered by recent public offering, expected to fund operations into...
December 2, 2023
Zotatifin plus Faslodex and Verzenio was granted as a Fast Track Designation for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer.
October 3, 2023
NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management firm, again showing support for the biopharma sector.
June 28, 2023
By Ben Glickman Shares of Genprex were higher early Wednesday after the company said it had received Fast Track Designation from the U.S. Food and Drug...
May 3, 2022
HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic (“pNETs”) and ...
May 2, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
July 16, 2021
Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ("EMA") has validate...